secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K
Filed at:   2023-03-31T23:59:59+00:00
Accession:  0001213900-23-025564
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ABVC BioPharma FY2022 net loss $16.3M, revenue up 173% but cash falls to $85k
-----------------------------------------------------------------------------

- Revenue $969,783, +173% YoY, driven by contract services with Rgene.
- Net loss $16.3M vs $12.0M in FY2021, increase of 36%.
- Operating expenses $15.8M, up from $12.1M, due to stock-based comp, SG&A, R&D.
- Working deficit $2.8M vs $3.7M working capital; cash $85k vs $5.8M.
- Pipeline: Vitargus Phase II trials in Australia/Thailand; ADHD ABV-1505 Phase II enrolling.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390023025564/0001213900-23-025564-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390023025564/ea176222-8k_abvcbio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-025564

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer